Moderna, a commercial-stage biotech, agreed to acquire OriCiro Genomics, a developer of a cell-free genome technology, for $85m. "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing. OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna," Stéphane Bancel, Moderna CEO.